Stephan A. Grupp, MD, PhD Children's Hospital of Philadelphia (CHOP)

Stephan Grupp, MD PhD, is Chief of the Cellular Therapy and Transplant Section, Director of the Cancer Immunotherapy Program, and Medical Director of The Cell and Gene Therapy Lab at the Children’s Hospital of Philadelphia, as well as the Yetta Dietch Novotny Professor of Pediatrics at the University of Pennsylvania.

His primary area of clinical research is the use of CAR T and other engineered cell therapies in relapsed pediatric cancers. He led all of the pediatric ALL trials of CTL019 (now approved as Kymriah), including the largest, most successful engineered T cell therapy clinical trial conducted to date (1, 2), as well as the global registration trial for CTL019 (3). His primary laboratory interest is the development of new cell therapy treatments for pediatric cancers.

1. Grupp et al., Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368, 1509 (Apr 18, 2013)<br>2. Maude et al., Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371, 1507 (Oct 16, 2014)<br>3. Maude et al., Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 378, 439 (Feb 1, 2018)